Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -232.26
- Piotroski Score 2.00
- Grade Neutral
- Symbol (HGEN)
- Company Humanigen, Inc.
- Price $0.04
- Changes Percentage (0%)
- Change $0.04
- Day Low $0.04
- Day High $0.04
- Year High $0.04
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/28/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.51
- Trailing P/E Ratio -0.0003921568627451
- Forward P/E Ratio -0.0003921568627451
- P/E Growth -0.0003921568627451
- Net Income $-70,238,000
Income Statement
Quarterly
Annual
Latest News of HGEN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Hgen draws on lessons from Tesla and SpaceX to drive down the cost of hydrogen
Hgen aims to revolutionize hydrogen production by optimizing electrolyzers to create green hydrogen efficiently. Their technology reduces costs and increases efficiency, offering a more sustainable al...
By TechCrunch | 2 weeks ago
